Altre lingue eFFECTOR Therapeutics, Inc.

Azioni

EFTR

US28202V2079

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 19/04/2024			Variaz. 5gg	Var. 1 gen.
1,7 ^USD	-4,49%		-18,27%	-85,45%

04/04	I principali ribassisti di mezzogiorno	MT
04/04	EFFECTOR Therapeutics, Inc. annuncia i risultati principali dello studio di Fase 2 KICKSTART di tomivosertib in combinazione con pembrolizumab nel carcinoma polmonare non a piccole cellule	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Health Care Down on Retreat From Risk -- Health Care Roundup	04/04
Top Midday Decliners	04/04
EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	04/04
EFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	04/04
Top Premarket Decliners	26/03
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	25/03
EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	05/02
EFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	25/01
EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024	09/01
EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024	09/01
EFFECTOR Therapeutics Announces Reverse Stock Split	09/01
EFFECTOR Therapeutics Announces Reverse Stock Split	09/01
EFFECTOR THERAPEUTICS ANNOUNCES NEW POSITIVE INTERIM DATA FROM DOSE ESCALATION AND PHASE 2 EXPANSION COHORTS OF ZOTATIFIN IN ER+ METASTATIC BREAST CANCER PATIENTS	11/12
EFFECTOR Therapeutics Says Study of Zotatifin in Breast Cancer Patients Yields 'Positive' Interim Data	08/12
EFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients	08/12
EFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients	08/12
EFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients	08/12
EFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer	28/11
EFFECTOR Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of Er+/Her2- Advanced Metastatic Breast Cancer	28/11
The role of STRIs in cancer	27/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue eFFECTOR Therapeutics, Inc.

Azioni

EFTR

US28202V2079

Altre lingue

Filtri